Kalinowski, D.S. and Richardson, D.R. (2007) Future of Toxicology-Iron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy. Chemical Research in Toxicology, 20, 715-720.
http://dx.doi.org/10.1021/tx700039c

has been cited by the following article:

• TITLE: Cu(II) Benzoylpyridine Thiosemicarbazone Complexes: Inhibition of Human Topoisomerase IIα and Activity against Breast Cancer Cells

  AUTHORS: Jennifer D. Conner, Wathsala Medawala, Madison T. Stephens, William H. Morris, Joseph E. Deweese, Patrick L. Kent, Jeffery J. Rice, Xiaohua Jiang, Edward C. Lisic

  KEYWORDS: Topoisomerase IIα, Alpha-(N)-Heterocyclic Thiosemicarbazones, Breast Cancer Cells

  JOURNAL NAME: Open Journal of Inorganic Chemistry, Vol.6 No.2, April 29, 2016

  ABSTRACT: The focus of this research is on the study of a series of copper (II) benzoylpyridine thiosemicarbazone complexes. Of the six benzoylpyridine thiosemicarbazone ligands used in this study, two are reported for the first time; 2-benzoylpyridine tert-butyl thiosemicarbazone (BZP-tBTSC), and 2-benzoylpyridine benzyl thiosemicarbazone (BZP-BzTSC). Once characterized by NMR, melting point, and MS, these mono-anionic tridentate ligands were then reacted with Cu2+ to form the new square planar metal complexes [Cu(BZP-tBTSC)Cl] and [Cu(BZP-BzTSC)Cl]. All of the copper complexes display marked inhibition of human topoisomerase IIα. The [Cu(BZP-tBTSC)Cl] complex shows marked activity against human breast cancer cell lines.